Italia markets open in 5 hours 12 minutes

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
14,55+1,96 (+15,57%)
Alla chiusura: 04:00PM EDT
14,56 +0,01 (+0,07%)
Dopo ore: 07:59PM EDT
Accedi per pubblicare un messaggio.
  • O
    Offer
    $EDIT conversation
    New player in the $EDIT 301 game $CRSP ctx 001 game. $DTIL and Novartis
  • i
    iamaverb
    $EDIT conversation
    $EDIT $BEAM
    New Comprehensive Map Ties Every Human Gene to Its Function

    The Human Genome Project was an ambitious initiative to sequence every piece of human DNA. The project drew together collaborators from research institutions around the world, including MIT’s Whitehead Institute for Biomedical Research, and was finally completed in 2003. Now, over two decades later, MIT Professor Jonathan Weissman and colleagues have gone beyond the sequence to present the first comprehensive functional map of genes that are expressed in human cells. The data from this project, published online on June 9, 2022, in the journal Cell, ties each gene to its job in the cell, and is the culmination of years of collaboration on the single-cell sequencing method Perturb-seq.

    The data are available for other scientists to use. “It’s a big resource in the way the human genome is a big resource, in that you can go in and do discovery-based research,” says Weissman, who is also a member of the Whitehead Institute and an investigator with the Howard Hughes Medical Institute. “Rather than defining ahead of time what biology you’re going to be looking at, you have this map of the genotype-phenotype relationships and you can go in and screen the database without having to do any experiments.”
  • J
    Johnson_Navin.R
    $BEAM conversation
    Since I don't foresee any news coming up in the near future for Base Editing and CRISPR, I have a contemporary question for the some on this board. Joe is on his way to Saudi Arabia to ask the Saudis to pump and sell more dirty oil to help lower the energy cost (and inflation) for Americans. America produces the cleanest oil and gas in the world so why doesn't he visit the Permian Basin in Texas or the Marcellus Shale in Pennsylvania where he is from and promote domestic production? Maybe I am missing something so what say you? $EDIT $BEAM
  • J
    Johnson_Navin.R
    $BEAM conversation
    This is definitely NOT the company's fault. $BEAM $EDIT
    We are in the midst of the longest, saddest, most excruciating, and unsatisfying "I told you so" in the history of the world.
  • J
    James
    $IMTX conversation
    The company and $EDIT have announced a research collaboration and licensing agreement. It is for Editas' gene-editing tech, which will be with the ACTallo platform.
  • J
    Johnson_Navin.R
    $BEAM conversation
    Who else believes the slow crash of the speculative 2 trillion dollar crypto market will contribute to putting pressure on genomic firms? I wish the bandaid would be ripped off, and investors would go from speculating to investing in technologies with a real future like $BEAM and $EDIT.
  • B
    Brent
    $CRBU conversation
    This reminds me of $EDIT and the response to their results back in October 2021. It sounded positive but further scrutiny and doubt set in ($EDIT is down 70% since then). The entire gene editing space has been clobbered these past few months. How much of it is monetary policy (risk on) vs. questions about the tech?
  • i
    iamaverb
    $EDIT conversation
    I am saddened to say, after getting back into $EDIT after the recent patent case results, I am totally out of $EDIT, taking a $3.50+- loss, as well as $BEAM, which I finally sold out at the end of March. I do believe both companies have the ability to make medical history in the future, but today's market is not one for speculating.
    I don't see this administration having any clear path forward during these trying times, other than to try to redirect our attention and distribute free cash handouts which won't fix anything. I will sit on the sidelines for the time being waiting for either the bottom which I predict is further down the road or for these two companies to actually report something of substance which, as both are saying, " ...in the second half of 2022". GLTA.
  • J
    Johnson_Navin.R
    $BEAM conversation
    Well, that didn't last too long. After getting drunk on euphoria yesterday, reality set back in when JoJo spoke and blamed everybody but himself for the current state of affairs. "Look, a squirrel".
    This is going to be a long, hot summer and fall. $BEAM $EDIT
  • i
    iamaverb
    $EDIT conversation
    I wrote this 24 days ago and was pounce upon by Mick for spreading fear. It appears to have come true today and is apparently shows up as pattern at Editas. EX-CEO Bosley infamously began the pattern years ago.
    iamaverb25 days ago
    $EDIT conversation
    Charlie, say it ain't so. The last time we had upper management sell so many shares in such a short amount of time that person was shown the door soon after. Ok, I get it, you received 225,000 stock options in 09.09.2016 which vested equally over the next 4 years, but why are you dumping this latest 25% of those shares so quickly?

    The company seams a little devious to me this morning by trying to bury Charlie's story with two additional pr's just minutes after his notice of departure. BTW, the company did release a new January presentation this morning also.
  • O
    Offer
    $CRSP conversation
    We should actually be happy about this market correction. Just imagine, if all the big 4 were trading at their highs now, what would we have thought to ourselves?
    Two things:
    1) These companies are the future. They will each be worth XXX (Fill in the blank according to your point of view).
    2) I wish I could have bought more at half the price.

    Well, guess what. These companies are still the future. Nothing in their story changed. And we got our chance to buy more shares in prices we thought we will never see again.

    Look at the glass half full.

    $EDIT $BEAM $NTLA $CRSP
  • O
    Offer
    $EDIT conversation
    We would like to welcome you on board on our flight to 100B valuation, we know you had other choices and we thank you for choosing the CRISPR Sector. Flight EDIT has a technical problem with the engine and will depart as soon as there is a new CSO.

    Special thanks go to our investors who are collecting dollars on this flight. Thanks again and see you at the destination.
    $EDIT $NTLA $CRSP $BEAM
  • i
    iamaverb
    $EDIT conversation
    CVC recently filed a motion for summary judgement to get Editas patents nullified in the Interference because certain inventors were left off of the original Cas-9 patents, which was the basis for the EU decision and filed for the court not to allow Editas to amend the patents.
    Broad filed a motion yesterday to add Dr. Luciano Marraffini to the original patents.

    "Broad requested authorization to file a responsive motion contingent on the grant of CVC Substantive Motion 3 for judgment under 35 U.S.C. § 102(f) that the
    involved Broad patents and application name the wrong inventors"
    by leaving Dr. Luciano Marraffini off of the patents.

    The PTAB decision
    "Accordingly, it is ORDERED that Broad is authorized to file a motion
    seeking to change the named inventors on its involved patents and application."

    CVC also wants to subpoena Marraffini and a Dr. Shuailiang Lin who might cast doubt on who invented first, but neither party wants to testify for CVC, and Broad is preparing their motion to quash the request.

    These proceedings are a game of chess

    $EDIT $CRSP
  • V
    VirginiaLova
    $CRSP conversation
    Crispr Therapeutics initiated with a Buy at SunTrust SunTrust CRSP
    Crispr Therapeutics initiated with a Buy at SunTrust SunTrust CRSP
    thefly.com
  • i
    iamaverb
    $EDIT conversation
    @Kenneth/Vara. It is mysterious but the numbers are coming from NASDAQ. They show 3 trades alone of 1,596,773 shares at 16:39:15, 16:57:46, and 17:09:22, with one of the trades cancelled at 16:54:57. These are of course among many other large trades at the end of the day. One possible explanation is the market makers have a deal with the large institutions to hold large numbers of shares in their accounts and then trade them after hours allowing the tutes' to unwind their short positions near or at at the session highs, instead of them having to cover their short positions on the open market which would normally drive the share price much higher. Regardless, something exciting is going on with $EDIT and $NTLA, which had 10x's the normal volume today.
    Does anyone care to speculate? One common denominator is the recent patent interference review, or is it just the end of the quarter house cleaning with the institutional holders?
  • i
    iamaverb
    $EDIT conversation
    Over the past 3 months, I have divested myself from the market, including half of my $BEAM, 90% of $EDIT, and most of LCID. Everything else is gone, as I believe the bottom isn't near. FYJB and your singular attention to everything that doesn't matter.
  • S
    Sean
    $EDIT conversation
    I remember a conversation with iamaverb some time ago. Here is a part of it:

    • iamaverb
    2 months ago
    $EDIT conversation
    I'm not advocating anyone do anything, but I sold 4,000 shares of ADVM at the close today, roughly half of my holdings, because I feel there may be a stock offering coming in the near future. The company last offered 60 million dollars of shares 1.5 years ago at $6.75 a share so this may be a good time for the company to take advantage of current market conditions. Regardless, I am keeping my powder dry by selling today and positioning my oil stocks for sale if and when Editas makes an announcement and replicates the recent rise in ADVM share price. US oil stockpiles fell by 9.5 million barrels last week and oil jumped 4.39% today so the trend is my friend. Could this be the perfect storm out on the horizon?
    Less
    ReplyReplies (14)
    4

    iamaverb
    2 months agoReplied to a reaction
    $EDIT conversation
    Sean thanks for recognizing the point as to why I bring up ADVM on this board. I expect even more spectacular gains once Editas actually shows the market they are players in the CRISPR game.
    Reply
    21
    A few posts later he says he sold the rest.

    Iamaverb…sometimes you should not even make eye contact
  • J
    J.R. Jackson
    $EDIT conversation
    When the Company reveals reclaimed vision in patients, $EDIT stock price. . . off the charts!
  • k
    kirdes
    $EDIT conversation
    $EDIT 2019-10-10 13G Sumitomo Mitsui Trust Holdings, Inc. bought 4,958,593 mil shares ...is 10% Edit company

    Nikko asset management Inc. bought 5 000 000 mil shares 2019-10-09 this is 10% EDIT company

    Two japan company bought 20% EDIT
  • V
    VirginiaLova
    $CRSP conversation
    In January 2021, Editas’ IND was accepted by the FDA. NOVEMBER 2021 Editas earnings update included the following:

    “EDIT-301 for Sickle Cell Disease
    Enrolling patients for initial dosing
    … The Phase 1/2 RUBY trial for the treatment of sickle cell disease is currently enrolling study participants and expects to begin dosing in the first half of 2022”

    $BEAM IND is nice but realistically looking at 2023 -2024 for a first data cut from $Beam or $Edit.

    Crsp partnership with $Vrtx looks more and more and more brilliant every day.